Financial Data
RXRX Financial Data
Revenue · Earnings · Margins · Balance Sheet · Cash Flow
RXRXRecursion Pharmaceuticals, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum60
- Value34
- Quality29
- Risk resilience58
- Sentiment—
Financial Data Overview
Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.
Quarterly Financial Statements
Updated Oct 31, 2026.
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Revenue | $7.67M | $6.47M | $35.54M | $5.18M |
| Gross Profit | -$3.82M | -$6.02M | $8.66M | -$24.42M |
| Operating Income | -$134.97M | -$128.51M | -$108.33M | -$172.2M |
| Net Income | -$131.01M | -$117.5M | -$108.12M | -$162.25M |
| EPS | -$0.25 | -$0.22 | -$0.21 | -$0.36 |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Operating Cash Flow | -$105.95M | -$81.1M | -$46.07M | -$117.36M |
| Capital Expenditure | -$1.96M | -$338K | -$1.24M | -$243K |
| Free Cash Flow | -$107.91M | -$81.44M | -$47.32M | -$117.6M |
| Net Cash Provided By Operating Activities | -$105.95M | -$81.1M | -$46.07M | -$117.36M |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Total Assets | $1.21B | $1.34B | $1.47B |
| Total Debt | $61.89M | $72.38M | $77.97M |
| Cash And Cash Equivalents | — | — | — |
| Total Liabilities | $297.67M | $314.75M | $343.27M |
| Total Stockholders Equity | $915M | $1.02B | $1.13B |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| P/E ratio | -3.67 | -3.49 | -4.87 | -3.39 |
| P/B ratio | 2.14 | 1.59 | 1.9 | 2.08 |
| P/S ratio | 254.78 | 251.08 | 60.62 | 421.51 |
| Debt To Equity | 0.07 | 0.07 | 0.07 | 0.08 |
| Free Cash Flow Yield | -5.52% | -5.01% | -2.20% | -5.39% |
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| P/E ratio | -3.67 | -3.49 | -4.87 | -3.39 |
| P/B ratio | 2.14 | 1.59 | 1.9 | 2.08 |
| P/S ratio | 254.78 | 251.08 | 60.62 | 421.51 |
| Return On Equity | -14.32% | -11.47% | -9.56% | -15.50% |
| Debt To Equity | 0.07 | 0.07 | 0.07 | 0.08 |
Current Stock Metrics
Current fundamental, technical, and risk readings in one place.
| Metric | Value |
|---|---|
| Pe | -3.2x |
| Pb | 1.94x |
| Gross Margin | -46.66% |
| Operating Margin | -991.72% |
| ROE | -50.41% |
| ROIC | -48.34% |
| Debt To Equity | 0.07 |
| FCF Yield | -20.28% |
As of Oct 30, 2026
| Metric | Value |
|---|---|
| Close | $4.03 |
| Volume | 20.52M |
| RSI (14) | 47.92 |
| MACD | 0.07 |
| MACD signal | 0.04 |
| MACD histogram | 0.03 |
| ADX (14) | 32.29 |
| SMA (50) | $3.73 |
| SMA (200) | $3.53 |
| ATR (14) | $0.35 |
| Historical volatility (annualized) | 122.31% |
| Volume (20-day average) | 31.23M |
As of Oct 30, 2026
| Metric | Value |
|---|---|
| Resilience score | 58/100 |
| Beta | 1.03 |
| Annual volatility | 73.46% |
| Max Drawdown | -51.62% |
| Sharpe Ratio | -0.13 |
| VaR (95%, 1-day) | -6.87% |
As of Oct 30, 2026
Detailed Metrics
Additional measures remain available here while the decision pages stay focused.
No additional fundamental metrics are available.
No additional technical indicators are available.
No additional risk measures are available.
Related Links
RXRX Financial Data FAQ
What is Recursion Pharmaceuticals, Inc.'s revenue?
Recursion Pharmaceuticals, Inc.'s revenue is one of the core financial data points for RXRX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is Recursion Pharmaceuticals, Inc.'s revenue growing?
Revenue growth shows whether Recursion Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is RXRX's EPS?
RXRX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is Recursion Pharmaceuticals, Inc.'s net income?
Recursion Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does Recursion Pharmaceuticals, Inc. generate?
Free cash flow shows how much cash Recursion Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does Recursion Pharmaceuticals, Inc. have?
Cash and debt help frame RXRX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.